BR9814729A - Método e composição de uma preparação oral de itraconazol - Google Patents

Método e composição de uma preparação oral de itraconazol

Info

Publication number
BR9814729A
BR9814729A BR9814729-3A BR9814729A BR9814729A BR 9814729 A BR9814729 A BR 9814729A BR 9814729 A BR9814729 A BR 9814729A BR 9814729 A BR9814729 A BR 9814729A
Authority
BR
Brazil
Prior art keywords
preparation
oral
composition
itraconazole
solid dispersions
Prior art date
Application number
BR9814729-3A
Other languages
English (en)
Inventor
Jae-Young Jung
Hye-Hyun Kim
Sang-Heon Lee
Ji-Woong Hong
Jong-Woo Park
Kyu-Hyun Lee
Original Assignee
Choongwae Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980027730A external-priority patent/KR100288890B1/ko
Application filed by Choongwae Pharma Corp filed Critical Choongwae Pharma Corp
Publication of BR9814729A publication Critical patent/BR9814729A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

"MéTODO E COMPOSIçãO DE UMA PREPARAçãO ORAL DE ITRACONAZOL". A presente invenção refere-se a um método e composição de uma preparação oral de itraconazol, uma excelente droga antifúngica azólica. Mais particularmente, refere-se a uma preparação oral de itraconazol tendo biodisponibilidade melhorada, que é preparada de acordo com as seguintes etapas: i). dissolver itraconazol e polímero hidrofílico com solvente; ii). secar dita mistura por pulverização, e iii) . preparar as dispersões sólidas para preparação oral. As dispersões sólidas preparadas na presente invenção podem ser úteis na preparação de comprimidos, grânulos e outras formas orais de dosagem.
BR9814729-3A 1997-12-31 1998-12-17 Método e composição de uma preparação oral de itraconazol BR9814729A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970081947 1997-12-31
KR1019980027730A KR100288890B1 (ko) 1997-12-31 1998-07-10 이트라코나졸 경구용 제제 및 그의 제조방법
PCT/KR1998/000436 WO1999033467A1 (en) 1997-12-31 1998-12-17 Method and composition of an oral preparation of itraconazole

Publications (1)

Publication Number Publication Date
BR9814729A true BR9814729A (pt) 2002-01-08

Family

ID=26633347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814729-3A BR9814729A (pt) 1997-12-31 1998-12-17 Método e composição de uma preparação oral de itraconazol

Country Status (14)

Country Link
US (1) US6485743B1 (pt)
EP (1) EP1039909B1 (pt)
JP (1) JP3696087B2 (pt)
CN (1) CN1153570C (pt)
AU (1) AU1511399A (pt)
BR (1) BR9814729A (pt)
CA (1) CA2317106C (pt)
DE (1) DE69808670T2 (pt)
ES (1) ES2185238T3 (pt)
HK (1) HK1034906A1 (pt)
PL (1) PL191181B1 (pt)
PT (1) PT1039909E (pt)
TR (1) TR200001880T2 (pt)
WO (1) WO1999033467A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
CA2396380C (en) * 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
DK1347747T3 (da) * 2000-12-22 2006-04-10 Baxter Int Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
WO2004004683A1 (en) * 2002-07-04 2004-01-15 Janssen Pharmaceutica N.V. Solid dispersions comprising two different polymer matrixes
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
ATE357235T1 (de) * 2003-01-14 2007-04-15 Cimex Pharma Ag Bioaequivalente zusammensetzung in der form einer festen dispersion enthaltend itraconazol und ein hydrophiles polymer
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
WO2007024971A2 (en) 2005-08-22 2007-03-01 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CN104105472A (zh) 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
CN110354132A (zh) 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
MX366829B (es) 2012-06-21 2019-07-25 Mayne Pharma Int Pty Ltd Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201591954A1 (ru) * 2013-04-12 2016-04-29 Вайом Байосайнсиз Пвт. Лтд. Композиция и состав противомикробных средств, способы их получения и способы лечения микробных инфекций
CN105491886B (zh) * 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
US10016500B2 (en) * 2014-03-05 2018-07-10 Professional Compounding Centers Of America Poloxamer-based pharmaceutical compositions for treating wounds
CN106573002A (zh) * 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
CN104688536B (zh) * 2015-02-03 2016-06-08 常州制药厂有限公司 一种伊曲康唑制剂的制备方法
TW202315634A (zh) 2015-03-03 2023-04-16 美商製藥公司 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
CN106511265A (zh) * 2016-11-16 2017-03-22 北京万全德众医药生物技术有限公司 一种含有伊曲康唑的口服溶液及其制备工艺
WO2019043427A1 (en) 2017-09-01 2019-03-07 Jordan Sweden Medical And Sterilization Company FAST SELF-DISPERSION DOSAGE FORMS OF DEFERASIROX
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
JPS57171428A (en) 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
JPH0774151B2 (ja) * 1987-10-12 1995-08-09 三井東圧化学株式会社 薬物の好ましくない官能的性質を隠蔽した散剤の製造方法
GB8908250D0 (en) 1989-04-12 1989-05-24 Fisons Plc Formulations
JP3034592B2 (ja) * 1990-11-20 2000-04-17 わかもと製薬株式会社 経口用固形製剤及びその製造法
AU661754B2 (en) 1992-02-12 1995-08-03 Janssen - Cilag - S.p.a. Liposomal itraconazole formulations
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
IL124935A (en) 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dissolvable fungicidal preparations contain itraconazole with improved bioavailability

Also Published As

Publication number Publication date
WO1999033467A1 (en) 1999-07-08
CA2317106A1 (en) 1999-07-08
EP1039909B1 (en) 2002-10-09
CN1285746A (zh) 2001-02-28
PL341566A1 (en) 2001-04-23
CA2317106C (en) 2004-11-23
US6485743B1 (en) 2002-11-26
ES2185238T3 (es) 2003-04-16
EP1039909A1 (en) 2000-10-04
JP3696087B2 (ja) 2005-09-14
TR200001880T2 (tr) 2000-11-21
HK1034906A1 (en) 2001-11-09
PL191181B1 (pl) 2006-03-31
JP2001527044A (ja) 2001-12-25
AU1511399A (en) 1999-07-19
CN1153570C (zh) 2004-06-16
DE69808670T2 (de) 2003-07-03
PT1039909E (pt) 2003-02-28
DE69808670D1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
BR9814729A (pt) Método e composição de uma preparação oral de itraconazol
BR0112014A (pt) Processo para a preparação de uma composição farmacêutica e, composição resultante
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
ATE538797T1 (de) Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
ES2178268T3 (es) Formulaciones de liberacion controlada.
WO2004010941A3 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
BR9913575A (pt) Composições compreendendo sais de amina simpatomimética inadequadas para uso ilegal
DE69906269D1 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
BR0210595A (pt) Regime de dosagem e composição farmacêutica para contracepção de emergência
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
SE0102055D0 (sv) New Compounds
BR9809571A (pt) Composição medicinal e processo para produzì-la
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0008341A (pt) Sol orgânico, composto sólido, processo de preração de um sol, e, utilização de um sol
BR9810711A (pt) Formulação tópica de pulverização antipruriginosa, e, processo para prevenção ou tratamento de prurido em um paciente
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação

Legal Events

Date Code Title Description
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/496, A61K 47/32, A61K 9/14, A61K 9/16, A61K 9/20, A61K 9/48, A61P 31/10

Ipc: A61K 31/495 (2008.01), A61K 9/14 (2008.01)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements